Nationwide Shortage of Cisplatin and Carboplatin Undermines Cancer Care in India

In the early days of June the medical establishments of the Republic of India have reported a pervasive depletion of the chemotherapeutic agents cisplatin and carboplatin, two medicines whose absence threatens to destabilise the continuity of curative protocols for a multitude of malignancies. Hospitals ranging from metropolitan teaching institutions to provincial government clinics have disclosed that their inventories have descended to levels insufficient for the scheduled administration of treatment cycles, thereby compelling oncologists to confront the prospect of postponement or substitution in circumstances hitherto considered untenable.

At the All India Institute of Medical Sciences, the central stock of cisplatin fell below ten vials by the twenty‑fourth of May, a figure that, when juxtaposed with the average fortnightly consumption of several hundred vials, illustrates a shortfall of a magnitude unlikely to be rectified through routine replenishment channels. Consequently, patients who had previously been assured of uninterrupted cycles have been instructed to procure the medication through private pharmacies at inflated prices, an arrangement that not only undermines the principle of equitable access but also augments the financial burden on families already encumbered by the high cost of oncological care.

Dr. Meera Sharma, chief oncologist at a leading private hospital in Mumbai, has cautioned that the interruption of cisplatin‑based regimens for diseases such as ovarian, lung, and head‑and‑neck cancers may diminish therapeutic efficacy, given that dose intensity has been historically correlated with survival outcomes in peer‑reviewed studies. She further noted that alternative agents, while existent, lack the same evidence base and may introduce additional toxicities, thereby rendering the scarcity not merely an inconvenience but a potentially mortal liability for patients whose disease trajectories depend upon precise pharmacologic timing.

In response to mounting inquiries, the Ministry of Health and Family Welfare issued a communique on the second of June asserting that the shortfall originated from delayed customs clearance of imported raw materials, a circumstance that the department claimed was being remedied through expedited waivers and supplementary tenders. The statement, however, omitted any concrete timetable for the arrival of new consignments, and failed to address the immediate exigencies confronting patients whose treatment windows are measured in weeks rather than months, thereby exposing a disjunction between rhetorical commitment and operational capability.

Observers of public policy have pointed out that the prevailing procurement architecture, which relies upon a single‑source foreign supplier for both cisplatin and carboplatin, engenders a systemic vulnerability whereby any disruption in the supply chain—be it logistical, regulatory, or commercial—can cascade into a nationwide deficiency, a flaw long warned of in prior health‑sector audits. Moreover, the lack of a transparent buffer stock policy, combined with the limited domestic manufacturing capacity sanctioned under the recent Pharmaceutical Policy, suggests an institutional inertia that privileges cost‑saving over resilience, a judgment that now appears ethically indefensible in the face of human lives imperilled by bureaucratic expediency.

To what extent does the current statutory framework governing the importation of essential oncology drugs oblige the Union Government to furnish demonstrable evidence that customs procedures have been executed with the diligence required by the Fundamental Right to Life enshrined in Article 21 of the Constitution, and does the absence of such proof not render the State vulnerable to claims of administrative negligence under established jurisprudence? Is the exclusive reliance upon a solitary foreign vendor for cisplatin and carboplatin compatible with the precautionary principle articulated in the National Health Policy 2017, which mandates diversification of sources to safeguard public health, and should a breach of this principle not invite scrutiny under the Administrative Law’s doctrine of legitimate expectation of uninterrupted service? Finally, might the expenditure of public funds on emergency procurement at premium rates, absent a transparent bidding process, not contravene the principles of fiscal responsibility prescribed by the Comptroller and Auditor General, thereby opening the possibility of legal challenge by civil society organisations intent on enforcing accountability for the misallocation of resources meant for the most vulnerable citizens?

Does the failure to maintain an adequate strategic reserve of life‑saving chemotherapeutic agents constitute a breach of the Ministry’s own guidelines issued in 2023, which stipulated a minimum six‑month buffer for high‑risk medicines, and if so, what remedial measures are authorized under the Public Procurement (Preference to Make in India) Act to compel corrective action against the agencies responsible for the lapse? Could the affected patients, collectively bearing the psychosocial and economic toll of delayed treatment, invoke the doctrine of equitable relief under the Consumer Protection Act, 2019, by asserting that the health establishments, acting as service providers, have violated the implied term of reasonable care in delivering prescribed therapy, thereby entitling them to compensation or specific performance? And, in the broader perspective of democratic governance, should Parliament not consider revising the existing regulatory architecture to institute a mandatory real‑time monitoring system for critical drug inventories, coupled with statutory penalties for non‑compliance, so as to align administrative practice with the constitutional promise of health as a fundamental right?

Published: June 4, 2026